Loading...

CNTX CONTEXT THERAPEUTICS INC Expansion Plans 8-K Filing

CNTX

CNTX

CONTEXT THERAPEUTICS INC

(CNTX)

2026 8-K

FDA Fast Track Approval

Corporate Presentation Update

Court Ruling Update

Judicial Agreement Filed

Corporate Presentation Update

Q3 Results Update

Stock Sale Update

Nasdaq Extension Granted

Reverse Stock Split

Investor Meetings

Clinical Trial Update

Nasdaq Notification

Clinical Trial Update

License Agreement

Board Appointments

Annual Meeting of Stockholders

Private Placement

FDA IND Application Submission

Bylaws Amendment

Amendment of Collaboration ...

Press Release and Corporate...

Regulation FD Disclosure

Compliance with Minimum Bid...

Annual Meeting of Stockholders

Financial Results and Disco...

Regulation FD Disclosure

Press Release and Corporate...

External Links:

On April 2, 2026, Context Therapeutics Inc. announced that the FDA granted Fast Track designation to its bispecific antibody CTIM-76 for treating platinum-resistant ovarian cancer after standard therapies. This designation supports expedited development and review of the drug for patients in need.

AI Assistant

CONTEXT THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.